AnaptysBio Inc logo

ANAB - AnaptysBio Inc News Story

$24.33 -0.6  -2.5%

Last Trade - 18/06/21

Sector
Healthcare
Size
Mid Cap
Market Cap £482.2m
Enterprise Value £206.8m
Revenue £51.6m
Position in Universe 3328th / 6927

BRIEF-AnaptysBio Says European Commission Approves Jemperli For Recurrent Or Advanced dMMR/MSI-H Endometrial Cancer In Europe

Fri 23rd April, 2021 5:03pm
April 23 (Reuters) - AnaptysBio Inc  ANAB.O :
    * EUROPEAN COMMISSION APPROVES JEMPERLI (DOSTARLIMAB), THE
FIRST
ANTI-PD-1 THERAPY APPROVED FOR RECURRENT OR ADVANCED DMMR/MSI-H
ENDOMETRIAL CANCER IN EUROPE
    * DUE TO RECEIVE 8% TO 25% ROYALTY ON GLOBAL NET SALES OF
DOSTARLIMAB

Source text for Eikon:  urn:newsml:reuters.com:*:nGNXTTSjJ
Further company coverage:  ANAB.O 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.